Tertomotide

DB12747InvestigationalVaccines

Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). It is a peptide... It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells.

Mechanism: Tertomotide targets an enzyme called telomerase. Telomerase is seldom found in normal cell types but is overexpressed in most cancer cells.
Curator reviewed
Code names: GV 1001

Resolves to

Compound

UNII55R7RG342OCAS915019-08-8

Targets

O14746TERT

What you can answer from here — as of December 08, 2022

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tertomotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account